Octapharma

Octapharma AG is a family-owned global healthcare company based in Lachen, Switzerland, founded in 1983 by Wolfgang Marguerre. It is a leading manufacturer of human protein products, focusing on developing and producing medicines derived from human plasma and cell lines. The company aims to enhance the quality of life for patients, particularly those with hemophilia, by offering safer and higher-quality therapies. The product portfolio of Octapharma includes treatments in three main therapeutic areas: hematology, immunotherapy, and critical care. In hematology, the company provides therapies for hemophilia and bleeding disorders, utilizing innovative technologies for safety. Its immunotherapy products address primary immunodeficiency syndromes and immune thrombocytopenia. In critical care, Octapharma offers products like OctaplasLG, a treated human plasma for transfusions. With a commitment to innovation and quality, Octapharma serves hospitals, healthcare providers, and patients in over 120 countries, reaching hundreds of thousands of patients each year. The company continues to expand its manufacturing capabilities and invest in research to improve patient outcomes in various medical conditions.